Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Serous carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Serous carcinoma. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2019-002474-30 Sponsor Protocol Number: 2019-002474-30 Start Date*: 2019-12-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: PERSONALIZED MOLECULAR DRIVEN SURGERY ACCORDING TO BRCA MUTATIONAL STATUS IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS WITH HIGH TUMOR LOAD
    Medical condition: ADVANCED OVARIAN CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054913 Serous cystadenocarcinoma ovary PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001623-12 Sponsor Protocol Number: MITO32 Start Date*: 2020-03-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: RANDOMIZED PHASE III MULTICENTRE STUDY INVESTIGATING THE ROLE OF LETROZOLE IN HEAVILY PRETREATED RECURRENT OVARIAN CANCER
    Medical condition: ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054913 Serous cystadenocarcinoma ovary PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003209-10 Sponsor Protocol Number: ML18583 Start Date*: 2005-10-18
    Sponsor Name:Tampere University Hospital
    Full Title: VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
    Medical condition: FIGO Stage III-IV serous epithelial ovarian carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000277-72 Sponsor Protocol Number: ARRAY-162-311 Start Date*: 2013-09-18
    Sponsor Name:Array BioPharma Inc.
    Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or...
    Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001472-38 Sponsor Protocol Number: APR-407 Start Date*: 2013-12-12
    Sponsor Name:Aprea Therapeutics AB
    Full Title: PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Withou...
    Medical condition: Recurrent high grade serous ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021045 10033131 Ovarian carcinoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Completed) SE (Completed) ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000265-67 Sponsor Protocol Number: APR-486 Start Date*: 2017-08-01
    Sponsor Name:Aprea Therapeutics AB
    Full Title: PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
    Medical condition: Platinum-resistant high grade serous ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003066-39 Sponsor Protocol Number: 10UCS2018 Start Date*: 2022-02-21
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial
    Medical condition: Patients with a low-grade serous epithelial carcinoma of the ovary (LGSCO) including cancer of fallopian tube and peritoneum, FIGO III-IV stage and with ER+ and/or PgR+ after primary surgery are el...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001434-29 Sponsor Protocol Number: VX-EC-2-2013 Start Date*: 2015-01-13
    Sponsor Name:AS Kevelt
    Full Title: A Phase II Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma.
    Medical condition: PrR negative papillary serous adenocarcinoma, endometroid type of endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014743 Endometrial carcinoma LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014747 Endometrial carcinoma recurrent LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033700 Papillary serous endometrial carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001627-39 Sponsor Protocol Number: GOG-0281 Start Date*: 2014-10-24
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer (GOG-0281)
    Medical condition: Recurrent low grade serous ovarian or peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-015082-31 Sponsor Protocol Number: M10-757 Start Date*: 2010-04-07
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer
    Medical condition: Recurrent high grade serous ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000902-40 Sponsor Protocol Number: EMR200066-012 Start Date*: 2013-12-20
    Sponsor Name:Merck KGaA
    Full Title: Phase II Randomized Double Blind Placebo controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Gr...
    Medical condition: Unresectable Low Grade Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002877-27 Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 Start Date*: 2023-07-06
    Sponsor Name:Cancer Trials Ireland
    Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P...
    Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026340 Malignant neoplasm of peritoneum, unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003439-18 Sponsor Protocol Number: D0810C00019 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor...
    Medical condition: platinum sensitive serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005018-76 Sponsor Protocol Number: S60857 Start Date*: 2019-01-14
    Sponsor Name:University Hospitals Leuven
    Full Title: An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive...
    Medical condition: endometrial stromal sarcoma uterine adenosarcoma endometrial carcinoma sex cord stromal tumors serous ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003883-36 Sponsor Protocol Number: CFTSp104 Start Date*: 2017-02-01
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: Single arm feasibility of multi-maintenance olaparib after disease recurrence in participants with platinum sensitive BRCAm high grade serous ovarian cancer
    Medical condition: platinum sensitive BRCAm high grade serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002888-10 Sponsor Protocol Number: SYD985.003 Start Date*: 2020-03-25
    Sponsor Name:Byondis BV
    Full Title: A single-arm phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma who pr...
    Medical condition: Recurrent, Advanced or Metastatic Endometrial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10014743 Endometrial carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004083-25 Sponsor Protocol Number: NOGGO-ov44 Start Date*: 2021-10-21
    Sponsor Name:NOGGO e.V.
    Full Title: Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer
    Medical condition: platinum-sensitive recurrent low-grade serous ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004807-42 Sponsor Protocol Number: CA116001 Start Date*: 2023-01-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Pla...
    Medical condition: Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002427-14 Sponsor Protocol Number: 1199.9 Start Date*: 2005-11-28
    Sponsor Name:Boehringer Ingelheim Ltd
    Full Title: A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment with BIBF 1120 Following Chemotherapy in Patients with Relapsed Ovarian Cancer
    Medical condition: Patients with relapsed ovarian carcinoma, fallopian tube carcinoma or primary peritoneal cancer of serous type who have responded to a 2nd, 3rd or 4th line chemotherapy regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:08:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA